Enorin 6000 Anti-Xa IU/0.6 ml (SC Injection)
0.6 ml pre-filled syringe: ৳ 575.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Enoxaparin sodium |
| Company | Eskayef pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of deep vein thrombosis
- Treatment of unstable angina and non-Q-wave myocardial infarction
- Prevention of thrombus formation in the extra-corporal circulation during haemodialysis
- Prophylaxis of venous thromboembolic disease (prevention of blood clot formation in the veins)
- Prophylaxis of venous thromboembolic disease in medical patients bedridden due to acute illness
Composition
- 20 mg Enoxaparin Sodium (BP) in 0.2 ml pre-filled syringe
- 40 mg Enoxaparin Sodium (BP) in 0.4 ml pre-filled syringe
- 60 mg Enoxaparin Sodium (BP) in 0.6 ml pre-filled syringe
- 80 mg Enoxaparin Sodium (BP) in 0.8 ml pre-filled syringe
Pharmacology
Low molecular weight heparin with high anti-Xa activity and low anti-lla or antithrombin activity. Does not increase bleeding time or notable modification of activated Partial Thromboplastin Time (aPTT). Primarily metabolised in the liver.
Dosage
- Subcutaneously 100 anti-Xa lU/kg twice daily for 10 days
- Subcutaneously 150 anti-Xa lU/kg once daily for 10 days
- Subcutaneously 100 anti-Xa lU/kg for prevention during hemodialysis
- Subcutaneously 2000 anti-Xa IU (0.2 ml) or 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days in general surgery patients
- Subcutaneously 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days in orthopedic surgery patients
- Subcutaneously 4000 anti-Xa IU (0.4 ml) once daily for 6-14 days in medical patients
Administration
- Instructions on injecting yourself with Enoxaparin Sodium Syringes
- Selecting your dose
- Injecting
Interaction
Recommended discontinuation of agents which affect hemostasis prior to Enorin therapy unless strictly indicated
Contraindications
- Known hypersensitivity to Enoxaparin Sodium, heparin or other low molecular weight heparins
- Active major bleeding and conditions with a high risk of uncontrolled hemorrhage including recent hemorrhagic stroke
Side Effects
- Haemorrhage (bleeding)
- Thrombocytopenia
- Elevations of serum aminotransferase
- Pain, bluish marks at injection sites
- Skin rash at injection sites
- Neuraxial hematomas with concurrent use of Enorin and spinal/epidural anesthesia
Pregnancy & Lactation
- Pregnancy category B
- No evidence of crossing the placental barrier
- Use during pregnancy only if clearly needed
- Unknown excretion in human milk
- Decision should be made whether to discontinue nursing or discontinue Enoxaparin, taking into account the importance of Enoxaparin to the mother and the known benefits of nursing
Precautions & Warnings
- Enorin should be injected by deep subcutaneous route in prophylactic and curative treatment
- Used with caution in conditions with increased potential for bleeding
- Recommended platelet counts measurement before and during treatment
Use in Special Populations
- No dosage adjustment necessary in elderly patients unless kidney function is impaired
- Observation for signs and symptoms of bleeding in patients with renal impairment
- Caution in hepatically impaired patients
Overdose Effects
Accidental overdosage may lead to hemorrhagic complications. Can be largely neutralized by the slow i.v. injection of protamine sulfate
Therapeutic Class
Parenteral anti-coagulants
Storage Conditions
Store in a cool and dry place, protect from light and moisture. Do not store above 25°C. Keep out of the reach of children